HVB MINI FUTURE BULL - ASTRAZENECA | Market Closed - BOERSE MUENCHEN 01:17:13 01/06/2024 am IST | ||
| 0.75 EUR | +38.89% |
|
| Current month | +22.95% | ||
| 1 month | +22.95% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 0.75 | +38.89% |
| 30/24/30 | 0.54 | +31.71% |
| 29/24/29 | 0.41 | -21.15% |
| 28/24/28 | 0.52 | -38.10% |
| 27/24/27 | 0.84 | -4.55% |
Real-time BOERSE MUENCHEN
Last update May 01, 2024 at 01:17 am IST
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HD52SM |
| ISIN | DE000HD52SM2 |
| Date issued | 26/04/2024 |
| Strike | 11,602 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.76 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.05 € |
|---|---|
| Lowest since issue | 0.4 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
155.1
USD
Average target price
172
USD
Spread / Average Target
+10.90%
- Stock Market
- Certificates
- Certificat
